an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr \<45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. * contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets \< 50,000/ul, pt or ptt \>1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. * a condition that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. * received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. * prior experimental treatment for pasc with immunoglobulins. * current medications include oral steroids or other immunosuppressive medications. * active participation in a clinical protocol which includes any intervention that may affect the results of the current study. * contraindication of intravenous immunoglobulins, including: * renal insufficiency (egfr\<45mmol/l) * iga deficiency * history of ischemic heart disease * peripheral vascular disease * cerebrovascular disease * previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity * alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. * previously documented anaphylaxis or severe systemic reaction to immunoglobulins, acetaminophen, or diphenhydramine. * a severe psychiatric condition, which based on the assessment of the study investigators, will impact the ability to complete the 12-week study course. exclusions for optional procedures: - contraindication to autonomic testing: refractory ventricular arrhythmias or symptomatic coronary artery disease. daily use of medications that would impact autonomic testing (e.g. beta-blockers).

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr \<45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. * contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets \< 50,000/ul, pt or ptt \>1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. * a condition that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. * received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. * prior experimental treatment for pasc with immunoglobulins. * current medications include oral steroids or other immunosuppressive medications. * active participation in a clinical protocol which includes any intervention that may affect the results of the current study. * contraindication of intravenous immunoglobulins, including: * renal insufficiency (egfr\<45mmol/l) * iga deficiency * history of ischemic heart disease * peripheral vascular disease * cerebrovascular disease * previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity * alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. * previously documented anaphylaxis or severe systemic reaction to immunoglobulins, acetaminophen, or diphenhydramine. * a severe psychiatric condition, which based on the assessment of the study investigators, will impact the ability to complete the 12-week study course. exclusions for optional procedures: - contraindication to autonomic testing: refractory ventricular arrhythmias or symptomatic coronary artery disease. daily use of medications that would impact autonomic testing (e.g. beta-blockers).

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. a condition that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to immunoglobulins, acetaminophen, or diphenhydramine. a severe psychiatric condition, which based on the assessment of the study investigators, will impact the ability to complete the 12-week study course. exclusions for optional procedures: - contraindication to autonomic testing: refractory ventricular arrhythmias or symptomatic coronary artery disease. daily use of medications that would impact autonomic testing (e.g. beta-blockers).

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. a condition that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to immunoglobulins, acetaminophen, or diphenhydramine. a severe psychiatric condition, which based on the assessment of the study investigators, will impact the ability to complete the 12-week study course. exclusions for optional procedures: - contraindication to autonomic testing: refractory ventricular arrhythmias or symptomatic coronary artery disease. daily use of medications that would impact autonomic testing (e.g. beta-blockers).

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. a condition prior to the diagnosis of covid-19 infection that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to immunoglobulins, acetaminophen, or diphenhydramine. a severe psychiatric condition, which based on the assessment of the study investigators, will impact the ability to complete the 12-week study course. exclusions for optional procedures: -contraindication to autonomic testing: refractory ventricular arrhythmias or symptomatic coronary artery disease. daily use of medications that would impact autonomic testing (e.g. beta-blockers).

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. a condition prior to the diagnosis of covid-19 infection that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to immunoglobulins, acetaminophen, or diphenhydramine. a severe psychiatric condition, which based on the assessment of the study investigators, will impact the ability to complete the 12-week study course. exclusions for optional procedures: -contraindication to autonomic testing: refractory ventricular arrhythmias or symptomatic coronary artery disease. daily use of medications that would impact autonomic testing (e.g. beta-blockers).

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. contraindication to autonomic testing, including refractory ventricular arrhythmias or symptomatic coronary artery disease. a condition prior to the diagnosis of covid-19 infection that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with iv steroids or immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. diabetes mellitus treated with medications or hba1c >6.5. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to steroids, immunoglobulins, acetaminophen, or diphenhydramine. positive quantiferon-tb gold test. a severe psychiatric condition prior to the diagnosis of covid-19, which based on the assessment of the study investigators, will significantly increase the risk of psychiatric side effects from iv steroids.

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. contraindication to autonomic testing, including refractory ventricular arrhythmias or symptomatic coronary artery disease. a condition prior to the diagnosis of covid-19 infection that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with iv steroids or immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. diabetes mellitus treated with medications or hba1c >6.5. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to steroids, immunoglobulins, acetaminophen, or diphenhydramine. positive quantiferon-tb gold test. a severe psychiatric condition prior to the diagnosis of covid-19, which based on the assessment of the study investigators, will significantly increase the risk of psychiatric side effects from iv steroids.

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. contraindication to autonomic testing, including refractory ventricular arrhythmias or symptomatic coronary artery disease. a condition prior to the diagnosis of covid-19 infection that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with iv steroids or immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. diabetes mellitus treated with medications or hba1c >6.5. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to steroids, immunoglobulins, acetaminophen, or diphenhydramine. active or latent tb as evidenced by history of respiratory symptoms or of untreated or partially treated tuberculosis or a chest radiograph showing active infection or residual changes indicative of untreated prior tb infection on a chest radiograph (e.g. calcified granulomas, gohn focus or complex, apical scarring). a severe psychiatric condition prior to the diagnosis of covid-19, which based on the assessment of the study investigators, will significantly increase the risk of psychiatric side effects from iv steroids.

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. contraindication to autonomic testing, including refractory ventricular arrhythmias or symptomatic coronary artery disease. a condition prior to the diagnosis of covid-19 infection that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with iv steroids or immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. diabetes mellitus treated with medications or hba1c >6.5. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to steroids, immunoglobulins, acetaminophen, or diphenhydramine. active or latent tb as evidenced by history of respiratory symptoms or of untreated or partially treated tuberculosis or a chest radiograph showing active infection or residual changes indicative of untreated prior tb infection on a chest radiograph (e.g. calcified granulomas, gohn focus or complex, apical scarring). a severe psychiatric condition prior to the diagnosis of covid-19, which based on the assessment of the study investigators, will significantly increase the risk of psychiatric side effects from iv steroids.

None

None

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. contraindication to autonomic testing, including refractory ventricular arrhythmias or symptomatic coronary artery disease. a condition prior to the diagnosis of covid-19 infection that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with iv steroids or immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. diabetes mellitus treated with medications or hba1c >6.5. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to steroids, immunoglobulins, acetaminophen, or diphenhydramine. active or latent tb as evidenced by history of respiratory symptoms or of untreated or partially treated tuberculosis or a chest radiograph showing active infection or residual changes indicative of untreated prior tb infection on a chest radiograph (e.g. calcified granulomas, gohn focus or complex, apical scarring). a severe psychiatric condition prior to the diagnosis of covid-19, which based on the assessment of the study investigators, will significantly increase the risk of psychiatric side effects from iv steroids.

an individual who meets any of the following criteria will be excluded from participation in this study: - for participants who have not completed a brain mri since onset of symptoms: inability to complete brain mri with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, egfr <45 mmol/l, pregnancy or lactation, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine. contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets < 50,000/ul, pt or ptt >1.5 x uln for the nih clinical center, or otherwise inability to complete the procedure. contraindication to autonomic testing, including refractory ventricular arrhythmias or symptomatic coronary artery disease. a condition prior to the diagnosis of covid-19 infection that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. this could include: traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy. received a sars-cov-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the course of the study. prior experimental treatment for pasc with iv steroids or immunoglobulins. current medications include oral steroids or other immunosuppressive medications. active participation in a clinical protocol which includes any intervention that may affect the results of the current study. diabetes mellitus treated with medications or hba1c >6.5. contraindication of intravenous immunoglobulins, including: renal insufficiency (egfr<45mmol/l) iga deficiency history of ischemic heart disease peripheral vascular disease cerebrovascular disease previously diagnosed hypercoagulability syndrome including antiphospholipid antibody syndrome, protein c/s deficiency, factor v leiden, antithrombin deficiency, mthfr homozygosity alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3.0 times the upper limit of normal.precluding the use of acetaminophen. previously documented anaphylaxis or severe systemic reaction to steroids, immunoglobulins, acetaminophen, or diphenhydramine. active or latent tb as evidenced by history of respiratory symptoms or of untreated or partially treated tuberculosis or a chest radiograph showing active infection or residual changes indicative of untreated prior tb infection on a chest radiograph (e.g. calcified granulomas, gohn focus or complex, apical scarring). a severe psychiatric condition prior to the diagnosis of covid-19, which based on the assessment of the study investigators, will significantly increase the risk of psychiatric side effects from iv steroids.